Zoetis, Inc. Hits New 52-Week Low at USD 111.00 Amid Decline

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 111.00 as of May 6, 2026. This marks a significant decline, with the stock's performance over the past year reflecting a decrease of 37.81%, contrasting sharply with the S&P 500's gain of 31.36% during the same period. The company, which boasts a market capitalization of USD 53,244 million, has a price-to-earnings (P/E) ratio of 20.00. Despite the recent downturn, Zoetis maintains a strong return on equity of 80.42%, indicating effective management efficiency. The firm also demonstrates a solid ability to service its debt, evidenced by a low debt-to-EBITDA ratio of 1.22 times. In terms of growth, Zoetis has reported an annual net sales growth rate of 8.16%, alongside positive results for the last six consecutive quarters. The stock's dividend yield stands at 1.71%, and it has consistently delivered strong operating cash flow, reaching a peak of USD 2,929 million. However, the stock's performance has been below par in both the long and near term, as it continues to navigate a challenging market landscape.